Founder and co-Managing Partner of Wanaka Capital Partners.Before establishing Wanaka Capital Partners in 2006, Ronen was a Partner at McKinsey & Company, serving clients in the Private Equity, Telecommunications, Aviation and Financial Services sectors across a broad range of strategic and corporate performance topics, both in Israel and in Europe. He advised large corporations, but also start-ups and investment firms. He joined the company in London, and in 2000 helped establish McKinsey’s practice in Israel. Prior to McKinsey Ronen worked in software services as a database specialist and project manager. Before that he served for seven years as a pilot and flight instructor in the Israeli Air Force, reaching the rank of Captain.He holds a dual BA in Economics and Management from Tel Aviv University, where he graduated with distinction in 1996, and an MBA from the Wharton School at the University of Pennsylvania.
Founder of three medical devices and two optical communication companies, with 13 years in executive roles in innovative medical device companies. Recent 8 years developing products for diabetics – President / CEO positions. Mr. Nagar is Author and co–author of 26 published patents and patent applications, most of which are devices for diabetics. Mr. Nagar has an M.Sc. in Electrical Engineering from the Technion.
Founder and managing partner of Top Notch Capital, Israel’s leading life science investment banking boutique. Mr. Gilboa is one of the most experienced Life Science investment bankers in Israel.He is an active Life Science entrepreneur and besides being one of InsuLine’s founders, he is a founder of additional 4 Medical Device and Pharmaceutical companies.Prior to the foundation of Top-Notch Capital, he has previously served as Head of Investment Banking and led the investment banking team of Discount Capital Markets, the investment banking arm of Discount Bank. Mr. Gilboa serves as BOD member on the boards several privately held, life science companies.Mr. Gilboa holds a Bachelor degree in Political Science from the TA University and MBA (Specialty in Finance) from the Tel-Aviv University
Prior to joining Insuline Medical Ron was Vice President and CEO of Teva Israel, Israel’s leading pharmaceutical company with annual sales of over $650M. During his 21 years at Teva and its subsidiaries, he held key positions as Vice President of Russia & Regional Markets International Group at 2008-2009, where he was responsible for the integration of Barr/Pliva into Teva and establishing the new region. From 2007-2008 he was Vice President of Commercial Affairs, International Group, where he led the Global SCM, Product Portfolio, Regulatory Affairs, Marketing and Business Development. In addition, he held several management positions, including Manger of Global Distribution Projects Team, Manger of BOOTS Unit In Israel and Sales & Marketing Manager in the Palestinian Authority. Until 2012 Ron served as Director of the Board at OXAR and Argon Works Ltd., the largest manufacturer and supplier of Industrial Gases in Israel. Prior to that, he was Active Chairman of the Board at Sicor Europe SA. Ron has an M.B.A, from the University of Tel-Aviv where he majored in information systems with secondary stream in Technology Management and Operational Systems.
As of 2004 the Chief Executive Officer of SHL Telemedizin in Germany. Eyal introduced the telemedicine concept to the German market, including remote monitoring of patients suffering from chronic disease like heart insufficiency, diabetes and lung disease. The introduction of new concepts requires close work with the different players in the German healthcare market as well as the German insurance companies. While establishing the company and penetrating the German market Eyal lived most of the years in Germany and therefore understands the German culture and speaks fluent German. Prior to SHL in Germany Eyal worked in the telecommunication arena with Comverse, bringing significant success in penetrating green field large customers in Europe and east Europe, Africa and far east Asia . Eyal served for eight years in the Israeli Air Force, reaching the rank of Major. He holds a BA in Economics and Management from Tel Aviv University
An associate professor and vice-dean of the Faculty of Biotechnology and Food Engineering at the Technion Haifa Israel. Marcelle Machluf holed a PhD degree from the Faculty of Chemical Engineering the unit of Biotechnology, Ben Gurion University Bear Sheva, in Liposomes and polymer delivery for vaccines development. Prof Machluf had a post-doctoral fellowship of five years experience in drug delivery, gene therapy and tissue engineering in Harvard Medical School, Boston MA, US. Professor Machluf laboratory focuses in developing scaffolds for tissue engineering of the heart, blood vessels and pancreas. Her group also develops and engineers drug and gene delivery systems for cancer therapy. Professor Machluf has published more then 40 papers and chapters in books and has 7 patent applications in national phase
The General Manager (since April 2011) of Teledata Networks Ltd - a high tech company which is a leading global provider of innovative Access Network solutions and products for telecom service providers.Prior to that, he served as CFO&VP Operations at Teledata since 2006. Between 1998– 2004, he worked in New York, as CFO of Tadiran Electronics Inc and later on as the President of Elisra Inc.Previously he was the Corporate Director of Finance of Tadiran Ltd. He holds an MBA degree from the Hebrew University in Jerusalem.
Mr. Ran Nussbaum is a managing partner and the co-founder of The Pontifax Group, who has established three funds with over $220M under management and over 30 portfolio companies. Over the past 8 years, Ran has been managing the group's activity alongside Mr. Tomer Kariv. He also served as CEO of Biomedix and Spearhead as well as Nasvax's Chairman of the Board. Prior to joining Pontifax, he was a partner at Israel's largest business intelligence and strategic consulting firm. Ran's real life experience in the life sciences arena coupled with a 10-year experience in the business intelligence field create a unique blend of skills, enabling him to support companies from inception to commercialization. His work revolves around constant and active involvement in companies, providing them with strategic and business development oversight. Ran serves as a board member of many of the group's portfolio companies including c CAM Pharma, Theracaot, Insuline, Eloxx, Roth CollPlant, Protab, Quiet, Fusimab Ltd and as Ocon chairman of the board.